SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing a notable pullback as Amazon Pharmacy's launch of Novo Nordisk's oral GLP-1 for weight loss, unavailable on HIMS's platform, intensifies competition in the telehealth weight management sector. This, coupled with a recent Bank of America downgrade citing potential margin pressure, has sparked a polarized community debate: many see the stock as "broken," while long-term investors highlight oversold conditions and strong fundamentals as a significant buying opportunity.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending amidst extreme price plunges, largely driven by persistently warm winter forecasts and ample natural gas supplies. The community is expressing widespread despair over significant losses, with many desperately hoping for an "arctic blast" or "polar vortex" to reverse the devastating trend for this highly volatile, leveraged ETF, while others question its long-term viability.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is actively trending following positive regulatory feedback that significantly de-risks its lead drug, sonelokimab, by allowing a Biologics License Application filing without additional trials. This pivotal development, coupled with recent analyst upgrades and upcoming investor events, has fueled extensive community speculation about a potential strategic acquisition, with many anticipating substantial upside from the biotech's de-risked asset.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending with heightened anticipation for its J.P. Morgan Healthcare Conference presentation, where updates on Briumvi's robust market adoption and 2026 guidance are highly awaited. Community sentiment is also notably buoyed by recent competitor setbacks that underscore Briumvi's strong profile, leading to active discussions around potential strategic acquisitions and the influence of short positions.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending as the market closely watches unfolding developments in Venezuela, with the US administration signaling that American oil companies could be heavily involved in revitalizing the nation's vast oil reserves. This potential for asset recovery and new investment is fueling bullish sentiment and discussions of significant upside. However, community conversations also highlight widespread concerns regarding market oversupply, political complexities, and the long-term feasibility of such ventures.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals (NBY) is generating significant buzz due to a special cash dividend, the strategic involvement of investor David Lazar, and high short interest fueling short squeeze speculation. The community is sharply divided, with many anticipating substantial upside while others warn of a pump-and-dump. Conversation is also driven by recent filings hinting at a strategic pivot towards blockchain or financial infrastructure, comparing NBY to other low-float, high-volatility plays.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited is experiencing intense trading activity following news of a significant private placement and an acquisition, coinciding with the expiration of its IPO lock-up period. This low-float international stock is generating widespread community discussion, with many anticipating a substantial short squeeze and comparing its trajectory to other highly volatile market movers. However, considerable caution is also being voiced, highlighting the speculative nature and potential for rapid price movements.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings (VWAV) is generating significant buzz following a series of strategic developments in its AI, defense, and drone technology sectors, including recent patent grants and acquisitions. The community is highly bullish, anticipating a major "parabolic" move or short squeeze driven by the stock's extremely low float and high institutional ownership, with many drawing comparisons to past high-growth stocks. Investors are also noting its "Strong Buy" rating from Nasdaq Dorsey Wright and successful pilot programs, signaling strong potential for commercialization and growth.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid intense community debate surrounding an ICE agent's fatal shooting in Minneapolis, with newly analyzed footage fueling polarizing arguments about justified force versus alleged government overreach. This contentious environment is further amplified by ongoing discussions about the release of "Epstein files" and President Trump's recent engagement with oil executives regarding Venezuela's energy sector. The stock remains highly sensitive to these significant political and social controversies, influencing investor sentiment and trading conversations.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

United States Natural Gas Fund (UNG) is experiencing extreme volatility as natural gas prices react to conflicting short-term weather forecasts and a recent larger-than-expected storage draw, which still points to ample overall supply. Community discussion reveals a sharp division, with some investors buying dips on hopes of a polar vortex and growing demand from AI data centers, while others continue to short, citing persistent oversupply and the instrument's historical 'widow maker' volatility and perceived market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tempus AI Stock Surges 82.4% in a Year: What's Driving It?

TEM shares are up 82.4% in a year as Genomics revenues surge, Data & Services scale, FDA clearances and EBITDA turns positive.

Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that James C. (Jim) Foster, Chair, President, and Chief Executive Officer (CEO), plans to retire, effective on May 5, 2026...

What Makes Charles River (CRL) a New Buy Stock

Charles River (CRL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue?

Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Charles River Laboratories International (NYSE:CRL) Hits New 1-Year High - Here's Why

Charles River Laboratories International (NYSE:CRL) Reaches New 1-Year High - Should You Buy...

Allspring Global Investments Holdings LLC Sells 113,185 Shares of Charles River Laboratories International, Inc. $CRL

Allspring Global Investments Holdings LLC decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 4.9% during the third quarter, according to...

Charles River Laboratories International, Inc. $CRL Shares Purchased by Boston Trust Walden Corp

Boston Trust Walden Corp raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 36.4% during the third quarter, according to the company in its most recent...

Charles River Laboratories International (NYSE:CRL) Reaches New 52-Week High - Time to Buy?

Charles River Laboratories International (NYSE:CRL) Hits New 1-Year High - Should You Buy...

Charles River Laboratories International, Inc. $CRL Stake Cut by Norris Perne & French LLP MI

Norris Perne & French LLP MI lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 92.0% during the 3rd quarter, according to the company in...

Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eighteen ratings firms that are covering the...

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Charles River Laboratories International Inc.

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Current Price	$220.91
Prev Close	$215.51
Open	$217.82
Dividend Yield	0.00%
50-Day Moving Average	$185.60
Beta	1.42
Avg. Volume	675,251.82
PE Ratio	-138.59

52-Week High	$217.89
52-Week Low	$91.86
Market Capitalization	$10.64B
EPS (Annual)	$0.1994
Price to Book	3.11
Revenue Per Employee	$201,491.99
Enterprise Value/EBITDA	N/A

CRL
Charles River Laboratories International Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRL News

CRLCharles River Laboratories International Inc.